New activity is brewing for Exact Sciences ( (EXAS) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. This form gives shareholders all the information they need to develop an informed vote. Read on to learn more about the proposed company action.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Exact Sciences Corporation has called a special meeting of stockholders, to be held virtually on February 20, 2026, to vote on a proposed merger with Abbott Laboratories under an Agreement and Plan of Merger signed on November 19, 2025. Under the terms outlined in the proxy statement dated January 9, 2026, Abbott’s wholly owned subsidiary, Badger Merger Sub I, Inc., would merge with and into Exact Sciences, making Exact a direct, wholly owned subsidiary of Abbott, and each outstanding share of Exact common stock would be converted into the right to receive $105 in cash, subject to certain conditions and appraisal rights under Delaware law. Exact’s board of directors has unanimously determined that the transaction is advisable and in the best interests of shareholders, is recommending they vote in favor of the merger agreement, an advisory proposal on merger-related executive compensation, and a potential adjournment of the meeting if additional proxy solicitations are needed, underscoring that failure to vote could effectively count against approval of the merger.
The most recent analyst rating on (EXAS) stock is a Hold with a $105.00 price target. To see the full list of analyst forecasts on Exact Sciences stock, see the EXAS Stock Forecast page.
Spark’s Take on EXAS Stock
According to Spark, TipRanks’ AI Analyst, EXAS is a Outperform.
Exact Sciences’ stock is bolstered by strong technical momentum and a positive corporate event with the merger announcement. However, profitability challenges and valuation concerns temper the overall score. The earnings call provided a positive outlook, but financial performance remains a critical area for improvement.
To see Spark’s full report on EXAS stock, click here.
More about Exact Sciences
Exact Sciences Corporation is a U.S.-based biotechnology company focused on molecular diagnostic tests, particularly in cancer screening and early detection, serving healthcare providers and patients in the broader diagnostics and life sciences market.
Average Trading Volume: 5,420,545
Technical Sentiment Signal: Buy
Current Market Cap: $19.3B
For an in-depth examination of EXAS stock, go to TipRanks’ Overview page.